Hematological Disorders Protocols / Clinical Studies

For information on these and other studies, referring physicians may e-mail protocolinfo@stjude.org or call our toll free physician referral line, 1-888-226-4343. If you are not a physician, please e-mail info@stjude.org for information on St. Jude studies.

 

A Phase I Trial of Bendamustine in Combination with Clofarabine and Etoposide in Pediatric Patients with Relapsed or Refractory Hematologic Malignancies

For: Relapsed or refractory hematologic malignancies

 
 

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus NK Cell Transplantation in Patients with Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

For: Relapsed or refractory hematologic malignancies

 
 

Combined Haploidentical and Umbilical Cord Blood Transplantation in Patients with Hematologic Malignancies Using A Reduced Intensity Preparative Regimen

For: Hematologic malignancies

 
 

KIR Mismatched Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation with a TLI Based Conditioning Regimen in Patients with Hematologic Malignancies

For: Hematological malignancies

 
 

A Pilot Feasibility Study of Gene Transfer for X-linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells

For: X-linked Severe Combined Immunodeficiency (SCID-X1)

 
 

Massive Iron Deposit Assessment Study

For: Iron overload (non-therapeutic)

 
 

A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination with Fludarabine and Cytarabine in Pediatric Patients with Refractory Leukemia or Myelodysplastic Syndrome

For: Relapsed or refractory leukemia or hematologic malignancies

 
 

Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen

For: High risk hematologic malignancies

 

Non St. Jude Protocols

 

A Phase 3 Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease

For: Sickle cell disease